Philipp E. Hartrampf

1.1k total citations
73 papers, 702 citations indexed

About

Philipp E. Hartrampf is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Philipp E. Hartrampf has authored 73 papers receiving a total of 702 indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Pulmonary and Respiratory Medicine, 33 papers in Radiology, Nuclear Medicine and Imaging and 22 papers in Oncology. Recurrent topics in Philipp E. Hartrampf's work include Prostate Cancer Treatment and Research (30 papers), Radiopharmaceutical Chemistry and Applications (26 papers) and Neuroendocrine Tumor Research Advances (16 papers). Philipp E. Hartrampf is often cited by papers focused on Prostate Cancer Treatment and Research (30 papers), Radiopharmaceutical Chemistry and Applications (26 papers) and Neuroendocrine Tumor Research Advances (16 papers). Philipp E. Hartrampf collaborates with scholars based in Germany, United States and Japan. Philipp E. Hartrampf's co-authors include Andreas K. Buck, Rudolf A. Werner, Constantin Lapa, Anna Katharina Seitz, Sebastian E. Serfling, Andreas Schirbel, Kerstin Michalski, Takahiro Higuchi, Steven P. Rowe and Hubert Kübler and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, Scientific Reports and International Journal of Molecular Sciences.

In The Last Decade

Philipp E. Hartrampf

68 papers receiving 694 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Philipp E. Hartrampf Germany	16	381	379	245	102	98	73	702
Aurora Poon Australia	16	328 0.9×	269 0.7×	163 0.7×	86 0.8×	159 1.6×	32	800
Laure Michaud France	13	336 0.9×	368 1.0×	269 1.1×	102 1.0×	55 0.6×	31	774
Duygu Has Şimşek Türkiye	13	219 0.6×	183 0.5×	275 1.1×	119 1.2×	91 0.9×	58	527
Shyam Tanguturi United States	14	238 0.6×	289 0.8×	150 0.6×	95 0.9×	97 1.0×	42	914
Fabrice Gutman France	10	391 1.0×	231 0.6×	233 1.0×	132 1.3×	146 1.5×	20	716
Zeynep Gözde Özkan Türkiye	14	217 0.6×	121 0.3×	243 1.0×	131 1.3×	92 0.9×	40	518
Ameya Puranik India	13	195 0.5×	165 0.4×	144 0.6×	98 1.0×	75 0.8×	105	551
Lucia Zanoni Italy	15	519 1.4×	638 1.7×	173 0.7×	86 0.8×	174 1.8×	50	1.0k
Amir H. Khandani United States	18	305 0.8×	377 1.0×	215 0.9×	59 0.6×	110 1.1×	59	759
A. Fernandes United States	13	157 0.4×	294 0.8×	207 0.8×	98 1.0×	66 0.7×	23	679

Countries citing papers authored by Philipp E. Hartrampf

Since Specialization

Citations

This map shows the geographic impact of Philipp E. Hartrampf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philipp E. Hartrampf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philipp E. Hartrampf more than expected).

Fields of papers citing papers by Philipp E. Hartrampf

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philipp E. Hartrampf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philipp E. Hartrampf. The network helps show where Philipp E. Hartrampf may publish in the future.

Co-authorship network of co-authors of Philipp E. Hartrampf

This figure shows the co-authorship network connecting the top 25 collaborators of Philipp E. Hartrampf. A scholar is included among the top collaborators of Philipp E. Hartrampf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philipp E. Hartrampf. Philipp E. Hartrampf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kalogirou, Charis, Simon Weber, Anna Katharina Seitz, et al.. (2025). Radioligand treatment with [177Lu]Lu-PSMA I&T in elderly Patients - Safety, efficacy, and prognostic factors for survival. European Journal of Nuclear Medicine and Molecular Imaging. 53(3). 1469–1478. 1 indexed citations

Serfling, Sebastian E., Philipp E. Hartrampf, Takahiro Higuchi, et al.. (2025). Somatostatin Receptor-Directed Theranostics in Esthesioneuroblastoma. Clinical Nuclear Medicine. 50(5). 363–367. 1 indexed citations

Hartrampf, Philipp E., Aleksander Kosmala, Alexander Kerscher, et al.. (2025). 131I SPECT/CT provides prognostic information in patients with differentiated thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging. 52(9). 3170–3179. 1 indexed citations

Müller, Miriam, Heribert Hänscheid, Sebastian E. Serfling, et al.. (2025). SSTR-directed peptide receptor radionuclide therapy for recurrent meningiomas: analysis of safety, efficacy and prognostic factors. European Journal of Nuclear Medicine and Molecular Imaging. 53(1). 116–127. 2 indexed citations

Michalski, Kerstin, Philipp E. Hartrampf, Sebastian E. Serfling, et al.. (2024). Volumetric Parameters Derived from CXCR4-Directed PET/CT Predict Outcome in Patients with Gastrointestinal Neuroendocrine Carcinomas. Molecular Imaging and Biology. 26(2). 344–350. 1 indexed citations

Hartrampf, Philipp E., Anna Katharina Seitz, Hubert Kübler, et al.. (2023). SUVmean on baseline [18F]PSMA-1007 PET and clinical parameters are associated with survival in prostate cancer patients scheduled for [177Lu]Lu-PSMA I&T. European Journal of Nuclear Medicine and Molecular Imaging. 50(11). 3465–3474. 21 indexed citations

Tomasik, Bartłomiej, Thorsten Alexander Bley, Jacek Jassem, et al.. (2023). Early biochemical and radiographic response after one cycle of [177Lu]Lu-PSMA I&T radioligand therapy in metastatic castration-resistant prostate cancer patients. European Journal of Nuclear Medicine and Molecular Imaging. 50(12). 3765–3776. 3 indexed citations

Kosmala, Aleksander, Toru Higuchi, Philipp E. Hartrampf, et al.. (2023). CXCR4-gerichtete PET/CT in 100 Patient:innen mit Marginalzonenlymphom -Diagnostische Performance, Vorhersagepotenzial und Eignung für CXCR4-Endoradiotherapie. Nuklearmedizin - NuclearMedicine. 62(2). 95–95. 1 indexed citations

Jilg, Cordula A., et al.. (2023). Prognostic value of tumor volume assessment on PSMA PET after [Lu-177]PSMA radioligand therapy evaluated by PSMA PET/CT consensus statement and RECIP 1.0. Nuklearmedizin - NuclearMedicine. 62(2). 88–89. 3 indexed citations

10.

Hartrampf, Philipp E., Philip Kollmannsberger, Antonio Giovanni Solimando, et al.. (2023). Predicting Microenvironment in CXCR4- and FAP-Positive Solid Tumors—A Pan-Cancer Machine Learning Workflow for Theranostic Target Structures. Cancers. 15(2). 392–392. 4 indexed citations

11.

Weich, Alexander, Sebastian E. Serfling, Takahiro Higuchi, et al.. (2023). Impact of CXCR4-Directed PET/CT on Staging and Proposed Oncologic Management in Patients With Digestive System Tumors. Clinical Nuclear Medicine. 48(7). 586–593. 7 indexed citations

12.

Lunger, Lukas, Christian H. Pfob, Constantin Lapa, et al.. (2023). Long-Term Nephrotoxicity of¹⁷⁷Lu-PSMA Radioligand Therapy. Journal of Nuclear Medicine. 65(1). 79–84. 28 indexed citations

13.

Hartrampf, Philipp E., et al.. (2022). Dose-Escalated Salvage Radiotherapy for Macroscopic Local Recurrence of Prostate Cancer in the Prostate-Specific Membrane Antigen Positron Emission Tomography Era. Cancers. 14(19). 4956–4956. 1 indexed citations

14.

Hartrampf, Philipp E., et al.. (2022). Salvage Nodal Radiotherapy as Metastasis-Directed Therapy for Oligorecurrent Prostate Cancer Detected by Positron Emission Tomography Shows Favorable Outcome in Long-Term Follow-Up. Cancers. 14(15). 3766–3766. 2 indexed citations

15.

Lewitzki, Victor, et al.. (2022). Health-related quality of life and clinical outcome after radiotherapy of patients with intracranial meningioma. Scientific Reports. 12(1). 19730–19730. 4 indexed citations

16.

Hartrampf, Philipp E., Anna Katharina Seitz, Sebastian E. Serfling, et al.. (2022). Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [177Lu]Lu-PSMA I&T during long-term follow-up. European Journal of Nuclear Medicine and Molecular Imaging. 49(12). 4262–4270. 21 indexed citations

17.

Hahner, Stefanie, Philipp E. Hartrampf, Britta Heinze, et al.. (2021). Targeting 11-Beta Hydroxylase With [131I]IMAZA: A Novel Approach for the Treatment of Advanced Adrenocortical Carcinoma. The Journal of Clinical Endocrinology & Metabolism. 107(4). e1348–e1355. 8 indexed citations

18.

Hänscheid, Heribert, Philipp E. Hartrampf, Andreas Schirbel, Andreas K. Buck, & Constantin Lapa. (2021). Intraindividual comparison of [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC. European Journal of Nuclear Medicine and Molecular Imaging. 48(8). 2566–2572. 12 indexed citations

19.

Hänscheid, Heribert, Andreas Schirbel, Philipp E. Hartrampf, et al.. (2021). Biokinetics and Dosimetry of [¹⁷⁷Lu]Lu-Pentixather. Journal of Nuclear Medicine. 63(5). jnumed.121.262295–jnumed.121.262295. 18 indexed citations

20.

Hartrampf, Philipp E., Heribert Hänscheid, Olivia Kertels, et al.. (2020). Long-term results of multimodal peptide receptor radionuclide therapy and fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma. Clinical and Translational Radiation Oncology. 22. 29–32. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact